RapamycinFungusV1, Main, Exploration, bibRecord, 000665

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Identifieur interne : 000665 ( Main/Exploration ); précédent : 000664; suivant : 000666

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Auteurs : Chadi Zakaria [Canada] ; Polen Sean [Canada] ; Huy-Dung Hoang [Canada] ; Louis-Phillipe Leroux [Canada] ; Margaret Watson [Canada] ; Samuel Tekeste Workenhe [Canada] ; Jaclyn Hearnden [Canada] ; Dana Pearl [Canada] ; Vinh Tai Truong [Canada] ; Nathaniel Robichaud [Canada] ; Akiko Yanagiya [Canada] ; Soroush Tahmasebi [Canada] ; Seyed Mehdi Jafarnejad [Canada] ; Jian-Jun Jia [Canada] ; Adrian Pelin [Canada] ; Jean-Simon Diallo [Canada] ; Fabrice Le Boeuf [Canada] ; John Cameron Bell [Canada] ; Karen Louise Mossman [Canada] ; Tyson Ernst Graber [Canada] ; Maritza Jaramillo [Canada] ; Nahum Sonenberg [Canada] ; Tommy Alain [Canada]

Source :

PLoS pathogens [ 1553-7374 ] ; 2018.

RBID : pubmed:30138450

Descripteurs français

KwdFr :
- Animaux (MeSH), Cellules HEK293 (MeSH), Cellules Vero (MeSH), Cellules cultivées (MeSH), Domaine catalytique (effets des médicaments et des substances chimiques), Facteur-4E d'initiation eucaryote (génétique), Facteur-4E d'initiation eucaryote (métabolisme), Herpès (anatomopathologie), Herpès (complications), Herpès (génétique), Herpèsvirus humain de type 1 (effets des médicaments et des substances chimiques), Herpèsvirus humain de type 1 (génétique), Humains (MeSH), Inhibiteurs de protéines kinases (pharmacologie), Organismes génétiquement modifiés (MeSH), Phosphoprotéines (génétique), Phosphoprotéines (métabolisme), Protéines adaptatrices de la transduction du signal (génétique), Protéines adaptatrices de la transduction du signal (métabolisme), Protéines précoces immédiates (déficit), Protéines précoces immédiates (génétique), Régulation de l'expression des gènes tumoraux (effets des médicaments et des substances chimiques), Souris (MeSH), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (composition chimique), Transduction du signal (génétique), Tumeurs (anatomopathologie), Tumeurs (complications), Tumeurs (génétique), Tumeurs (virologie), Ubiquitin-protein ligases (déficit), Ubiquitin-protein ligases (génétique).
MESH :
- anatomopathologie : Herpès, Tumeurs.
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- composition chimique : Herpès, Sérine-thréonine kinases TOR, Tumeurs.
- déficit : Protéines précoces immédiates, Ubiquitin-protein ligases.
- effets des médicaments et des substances chimiques : Domaine catalytique, Herpèsvirus humain de type 1, Régulation de l'expression des gènes tumoraux.
- génétique : Facteur-4E d'initiation eucaryote, Herpès, Herpèsvirus humain de type 1, Phosphoprotéines, Protéines adaptatrices de la transduction du signal, Protéines précoces immédiates, Transduction du signal, Tumeurs, Ubiquitin-protein ligases.
- métabolisme : Facteur-4E d'initiation eucaryote, Phosphoprotéines, Protéines adaptatrices de la transduction du signal.
- pharmacologie : Inhibiteurs de protéines kinases.
- virologie : Tumeurs.
- Animaux, Cellules HEK293, Cellules Vero, Cellules cultivées, Humains, Organismes génétiquement modifiés, Souris.

English descriptors

KwdEn :
- Adaptor Proteins, Signal Transducing (genetics), Adaptor Proteins, Signal Transducing (metabolism), Animals (MeSH), Catalytic Domain (drug effects), Cells, Cultured (MeSH), Chlorocebus aethiops (MeSH), Eukaryotic Initiation Factor-4E (genetics), Eukaryotic Initiation Factor-4E (metabolism), Gene Expression Regulation, Neoplastic (drug effects), HEK293 Cells (MeSH), Herpes Simplex (complications), Herpes Simplex (genetics), Herpes Simplex (pathology), Herpesvirus 1, Human (drug effects), Herpesvirus 1, Human (genetics), Humans (MeSH), Immediate-Early Proteins (deficiency), Immediate-Early Proteins (genetics), Mice (MeSH), Neoplasms (complications), Neoplasms (genetics), Neoplasms (pathology), Neoplasms (virology), Organisms, Genetically Modified (MeSH), Phosphoproteins (genetics), Phosphoproteins (metabolism), Protein Kinase Inhibitors (pharmacology), Signal Transduction (genetics), TOR Serine-Threonine Kinases (antagonists & inhibitors), TOR Serine-Threonine Kinases (chemistry), Ubiquitin-Protein Ligases (deficiency), Ubiquitin-Protein Ligases (genetics), Vero Cells (MeSH).
MESH :
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- chemical , chemistry : TOR Serine-Threonine Kinases.
- chemical , deficiency : Immediate-Early Proteins, Ubiquitin-Protein Ligases.
- chemical , genetics : Adaptor Proteins, Signal Transducing, Eukaryotic Initiation Factor-4E, Immediate-Early Proteins, Phosphoproteins, Ubiquitin-Protein Ligases.
- chemical , metabolism : Adaptor Proteins, Signal Transducing, Eukaryotic Initiation Factor-4E, Phosphoproteins.
- complications : Herpes Simplex, Neoplasms.
- drug effects : Catalytic Domain, Gene Expression Regulation, Neoplastic, Herpesvirus 1, Human.
- genetics : Herpes Simplex, Herpesvirus 1, Human, Neoplasms, Signal Transduction.
- pathology : Herpes Simplex, Neoplasms.
- chemical , pharmacology : Protein Kinase Inhibitors.
- virology : Neoplasms.
- Animals, Cells, Cultured, Chlorocebus aethiops, HEK293 Cells, Humans, Mice, Organisms, Genetically Modified, Vero Cells.

Abstract

Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0 (ICP0)-deleted HSV1 (HSV1-dICP0), we found that asTORi markedly augment infection in cancer cells and a mouse mammary cancer xenograft. Mechanistically, asTORi repressed mRNA translation in normal cells, resulting in defective antiviral response but also inhibition of HSV1-dICP0 replication. asTORi also reduced antiviral response in cancer cells, however in contrast to normal cells, transformed cells and cells transduced to elevate the expression of eukaryotic initiation factor 4E (eIF4E) or to silence the repressors eIF4E binding proteins (4E-BPs), selectively maintained HSV1-dICP0 protein synthesis during asTORi treatment, ultimately supporting increased viral replication. Our data show that altered eIF4E/4E-BPs expression can act to promote HSV1-dICP0 infection under prolonged mTOR inhibition. Thus, pharmacoviral combination of asTORi and HSV1 can target cancer cells displaying dysregulated eIF4E/4E-BPs axis.

DOI: 10.1371/journal.ppat.1007264
PubMed: 30138450
PubMed Central: PMC6124814

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000474
to stream Main, to step Curation: 000474

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.</title>
<author><name sortKey="Zakaria, Chadi" sort="Zakaria, Chadi" uniqKey="Zakaria C" first="Chadi" last="Zakaria">Chadi Zakaria</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Sean, Polen" sort="Sean, Polen" uniqKey="Sean P" first="Polen" last="Sean">Polen Sean</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Hoang, Huy Dung" sort="Hoang, Huy Dung" uniqKey="Hoang H" first="Huy-Dung" last="Hoang">Huy-Dung Hoang</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leroux, Louis Phillipe" sort="Leroux, Louis Phillipe" uniqKey="Leroux L" first="Louis-Phillipe" last="Leroux">Louis-Phillipe Leroux</name>
<affiliation wicri:level="1"><nlm:affiliation>INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>INRS Institut Armand-Frappier Research Centre, Laval, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Watson, Margaret" sort="Watson, Margaret" uniqKey="Watson M" first="Margaret" last="Watson">Margaret Watson</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Workenhe, Samuel Tekeste" sort="Workenhe, Samuel Tekeste" uniqKey="Workenhe S" first="Samuel Tekeste" last="Workenhe">Samuel Tekeste Workenhe</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hearnden, Jaclyn" sort="Hearnden, Jaclyn" uniqKey="Hearnden J" first="Jaclyn" last="Hearnden">Jaclyn Hearnden</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Pearl, Dana" sort="Pearl, Dana" uniqKey="Pearl D" first="Dana" last="Pearl">Dana Pearl</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Truong, Vinh Tai" sort="Truong, Vinh Tai" uniqKey="Truong V" first="Vinh Tai" last="Truong">Vinh Tai Truong</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Robichaud, Nathaniel" sort="Robichaud, Nathaniel" uniqKey="Robichaud N" first="Nathaniel" last="Robichaud">Nathaniel Robichaud</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Yanagiya, Akiko" sort="Yanagiya, Akiko" uniqKey="Yanagiya A" first="Akiko" last="Yanagiya">Akiko Yanagiya</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Tahmasebi, Soroush" sort="Tahmasebi, Soroush" uniqKey="Tahmasebi S" first="Soroush" last="Tahmasebi">Soroush Tahmasebi</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Jafarnejad, Seyed Mehdi" sort="Jafarnejad, Seyed Mehdi" uniqKey="Jafarnejad S" first="Seyed Mehdi" last="Jafarnejad">Seyed Mehdi Jafarnejad</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Jia, Jian Jun" sort="Jia, Jian Jun" uniqKey="Jia J" first="Jian-Jun" last="Jia">Jian-Jun Jia</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pelin, Adrian" sort="Pelin, Adrian" uniqKey="Pelin A" first="Adrian" last="Pelin">Adrian Pelin</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Diallo, Jean Simon" sort="Diallo, Jean Simon" uniqKey="Diallo J" first="Jean-Simon" last="Diallo">Jean-Simon Diallo</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Le Boeuf, Fabrice" sort="Le Boeuf, Fabrice" uniqKey="Le Boeuf F" first="Fabrice" last="Le Boeuf">Fabrice Le Boeuf</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bell, John Cameron" sort="Bell, John Cameron" uniqKey="Bell J" first="John Cameron" last="Bell">John Cameron Bell</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mossman, Karen Louise" sort="Mossman, Karen Louise" uniqKey="Mossman K" first="Karen Louise" last="Mossman">Karen Louise Mossman</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Graber, Tyson Ernst" sort="Graber, Tyson Ernst" uniqKey="Graber T" first="Tyson Ernst" last="Graber">Tyson Ernst Graber</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jaramillo, Maritza" sort="Jaramillo, Maritza" uniqKey="Jaramillo M" first="Maritza" last="Jaramillo">Maritza Jaramillo</name>
<affiliation wicri:level="1"><nlm:affiliation>INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>INRS Institut Armand-Frappier Research Centre, Laval, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sonenberg, Nahum" sort="Sonenberg, Nahum" uniqKey="Sonenberg N" first="Nahum" last="Sonenberg">Nahum Sonenberg</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Alain, Tommy" sort="Alain, Tommy" uniqKey="Alain T" first="Tommy" last="Alain">Tommy Alain</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30138450</idno>
<idno type="pmid">30138450</idno>
<idno type="doi">10.1371/journal.ppat.1007264</idno>
<idno type="pmc">PMC6124814</idno>
<idno type="wicri:Area/Main/Corpus">000474</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000474</idno>
<idno type="wicri:Area/Main/Curation">000474</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000474</idno>
<idno type="wicri:Area/Main/Exploration">000474</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.</title>
<author><name sortKey="Zakaria, Chadi" sort="Zakaria, Chadi" uniqKey="Zakaria C" first="Chadi" last="Zakaria">Chadi Zakaria</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Sean, Polen" sort="Sean, Polen" uniqKey="Sean P" first="Polen" last="Sean">Polen Sean</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Hoang, Huy Dung" sort="Hoang, Huy Dung" uniqKey="Hoang H" first="Huy-Dung" last="Hoang">Huy-Dung Hoang</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leroux, Louis Phillipe" sort="Leroux, Louis Phillipe" uniqKey="Leroux L" first="Louis-Phillipe" last="Leroux">Louis-Phillipe Leroux</name>
<affiliation wicri:level="1"><nlm:affiliation>INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>INRS Institut Armand-Frappier Research Centre, Laval, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Watson, Margaret" sort="Watson, Margaret" uniqKey="Watson M" first="Margaret" last="Watson">Margaret Watson</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Workenhe, Samuel Tekeste" sort="Workenhe, Samuel Tekeste" uniqKey="Workenhe S" first="Samuel Tekeste" last="Workenhe">Samuel Tekeste Workenhe</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hearnden, Jaclyn" sort="Hearnden, Jaclyn" uniqKey="Hearnden J" first="Jaclyn" last="Hearnden">Jaclyn Hearnden</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Pearl, Dana" sort="Pearl, Dana" uniqKey="Pearl D" first="Dana" last="Pearl">Dana Pearl</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Truong, Vinh Tai" sort="Truong, Vinh Tai" uniqKey="Truong V" first="Vinh Tai" last="Truong">Vinh Tai Truong</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Robichaud, Nathaniel" sort="Robichaud, Nathaniel" uniqKey="Robichaud N" first="Nathaniel" last="Robichaud">Nathaniel Robichaud</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Yanagiya, Akiko" sort="Yanagiya, Akiko" uniqKey="Yanagiya A" first="Akiko" last="Yanagiya">Akiko Yanagiya</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Tahmasebi, Soroush" sort="Tahmasebi, Soroush" uniqKey="Tahmasebi S" first="Soroush" last="Tahmasebi">Soroush Tahmasebi</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Jafarnejad, Seyed Mehdi" sort="Jafarnejad, Seyed Mehdi" uniqKey="Jafarnejad S" first="Seyed Mehdi" last="Jafarnejad">Seyed Mehdi Jafarnejad</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Jia, Jian Jun" sort="Jia, Jian Jun" uniqKey="Jia J" first="Jian-Jun" last="Jia">Jian-Jun Jia</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pelin, Adrian" sort="Pelin, Adrian" uniqKey="Pelin A" first="Adrian" last="Pelin">Adrian Pelin</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Diallo, Jean Simon" sort="Diallo, Jean Simon" uniqKey="Diallo J" first="Jean-Simon" last="Diallo">Jean-Simon Diallo</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Le Boeuf, Fabrice" sort="Le Boeuf, Fabrice" uniqKey="Le Boeuf F" first="Fabrice" last="Le Boeuf">Fabrice Le Boeuf</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bell, John Cameron" sort="Bell, John Cameron" uniqKey="Bell J" first="John Cameron" last="Bell">John Cameron Bell</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mossman, Karen Louise" sort="Mossman, Karen Louise" uniqKey="Mossman K" first="Karen Louise" last="Mossman">Karen Louise Mossman</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Graber, Tyson Ernst" sort="Graber, Tyson Ernst" uniqKey="Graber T" first="Tyson Ernst" last="Graber">Tyson Ernst Graber</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jaramillo, Maritza" sort="Jaramillo, Maritza" uniqKey="Jaramillo M" first="Maritza" last="Jaramillo">Maritza Jaramillo</name>
<affiliation wicri:level="1"><nlm:affiliation>INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>INRS Institut Armand-Frappier Research Centre, Laval, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sonenberg, Nahum" sort="Sonenberg, Nahum" uniqKey="Sonenberg N" first="Nahum" last="Sonenberg">Nahum Sonenberg</name>
<affiliation wicri:level="4"><nlm:affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
<orgName type="university">Université McGill</orgName>
</affiliation>
</author>
<author><name sortKey="Alain, Tommy" sort="Alain, Tommy" uniqKey="Alain T" first="Tommy" last="Alain">Tommy Alain</name>
<affiliation wicri:level="1"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">PLoS pathogens</title>
<idno type="eISSN">1553-7374</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptor Proteins, Signal Transducing (genetics)</term>
<term>Adaptor Proteins, Signal Transducing (metabolism)</term>
<term>Animals (MeSH)</term>
<term>Catalytic Domain (drug effects)</term>
<term>Cells, Cultured (MeSH)</term>
<term>Chlorocebus aethiops (MeSH)</term>
<term>Eukaryotic Initiation Factor-4E (genetics)</term>
<term>Eukaryotic Initiation Factor-4E (metabolism)</term>
<term>Gene Expression Regulation, Neoplastic (drug effects)</term>
<term>HEK293 Cells (MeSH)</term>
<term>Herpes Simplex (complications)</term>
<term>Herpes Simplex (genetics)</term>
<term>Herpes Simplex (pathology)</term>
<term>Herpesvirus 1, Human (drug effects)</term>
<term>Herpesvirus 1, Human (genetics)</term>
<term>Humans (MeSH)</term>
<term>Immediate-Early Proteins (deficiency)</term>
<term>Immediate-Early Proteins (genetics)</term>
<term>Mice (MeSH)</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (genetics)</term>
<term>Neoplasms (pathology)</term>
<term>Neoplasms (virology)</term>
<term>Organisms, Genetically Modified (MeSH)</term>
<term>Phosphoproteins (genetics)</term>
<term>Phosphoproteins (metabolism)</term>
<term>Protein Kinase Inhibitors (pharmacology)</term>
<term>Signal Transduction (genetics)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
<term>TOR Serine-Threonine Kinases (chemistry)</term>
<term>Ubiquitin-Protein Ligases (deficiency)</term>
<term>Ubiquitin-Protein Ligases (genetics)</term>
<term>Vero Cells (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Cellules HEK293 (MeSH)</term>
<term>Cellules Vero (MeSH)</term>
<term>Cellules cultivées (MeSH)</term>
<term>Domaine catalytique (effets des médicaments et des substances chimiques)</term>
<term>Facteur-4E d'initiation eucaryote (génétique)</term>
<term>Facteur-4E d'initiation eucaryote (métabolisme)</term>
<term>Herpès (anatomopathologie)</term>
<term>Herpès (complications)</term>
<term>Herpès (génétique)</term>
<term>Herpèsvirus humain de type 1 (effets des médicaments et des substances chimiques)</term>
<term>Herpèsvirus humain de type 1 (génétique)</term>
<term>Humains (MeSH)</term>
<term>Inhibiteurs de protéines kinases (pharmacologie)</term>
<term>Organismes génétiquement modifiés (MeSH)</term>
<term>Phosphoprotéines (génétique)</term>
<term>Phosphoprotéines (métabolisme)</term>
<term>Protéines adaptatrices de la transduction du signal (génétique)</term>
<term>Protéines adaptatrices de la transduction du signal (métabolisme)</term>
<term>Protéines précoces immédiates (déficit)</term>
<term>Protéines précoces immédiates (génétique)</term>
<term>Régulation de l'expression des gènes tumoraux (effets des médicaments et des substances chimiques)</term>
<term>Souris (MeSH)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérine-thréonine kinases TOR (composition chimique)</term>
<term>Transduction du signal (génétique)</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (complications)</term>
<term>Tumeurs (génétique)</term>
<term>Tumeurs (virologie)</term>
<term>Ubiquitin-protein ligases (déficit)</term>
<term>Ubiquitin-protein ligases (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Immediate-Early Proteins</term>
<term>Ubiquitin-Protein Ligases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Adaptor Proteins, Signal Transducing</term>
<term>Eukaryotic Initiation Factor-4E</term>
<term>Immediate-Early Proteins</term>
<term>Phosphoproteins</term>
<term>Ubiquitin-Protein Ligases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adaptor Proteins, Signal Transducing</term>
<term>Eukaryotic Initiation Factor-4E</term>
<term>Phosphoproteins</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Herpès</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Herpes Simplex</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Herpès</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Catalytic Domain</term>
<term>Gene Expression Regulation, Neoplastic</term>
<term>Herpesvirus 1, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Protéines précoces immédiates</term>
<term>Ubiquitin-protein ligases</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Domaine catalytique</term>
<term>Herpèsvirus humain de type 1</term>
<term>Régulation de l'expression des gènes tumoraux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Herpes Simplex</term>
<term>Herpesvirus 1, Human</term>
<term>Neoplasms</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Facteur-4E d'initiation eucaryote</term>
<term>Herpès</term>
<term>Herpèsvirus humain de type 1</term>
<term>Phosphoprotéines</term>
<term>Protéines adaptatrices de la transduction du signal</term>
<term>Protéines précoces immédiates</term>
<term>Transduction du signal</term>
<term>Tumeurs</term>
<term>Ubiquitin-protein ligases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur-4E d'initiation eucaryote</term>
<term>Phosphoprotéines</term>
<term>Protéines adaptatrices de la transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Herpes Simplex</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protein Kinase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cells, Cultured</term>
<term>Chlorocebus aethiops</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Mice</term>
<term>Organisms, Genetically Modified</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules HEK293</term>
<term>Cellules Vero</term>
<term>Cellules cultivées</term>
<term>Humains</term>
<term>Organismes génétiquement modifiés</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0 (ICP0)-deleted HSV1 (HSV1-dICP0), we found that asTORi markedly augment infection in cancer cells and a mouse mammary cancer xenograft. Mechanistically, asTORi repressed mRNA translation in normal cells, resulting in defective antiviral response but also inhibition of HSV1-dICP0 replication. asTORi also reduced antiviral response in cancer cells, however in contrast to normal cells, transformed cells and cells transduced to elevate the expression of eukaryotic initiation factor 4E (eIF4E) or to silence the repressors eIF4E binding proteins (4E-BPs), selectively maintained HSV1-dICP0 protein synthesis during asTORi treatment, ultimately supporting increased viral replication. Our data show that altered eIF4E/4E-BPs expression can act to promote HSV1-dICP0 infection under prolonged mTOR inhibition. Thus, pharmacoviral combination of asTORi and HSV1 can target cancer cells displaying dysregulated eIF4E/4E-BPs axis.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30138450</PMID>
<DateCompleted><Year>2019</Year>
<Month>01</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>8</Issue>
<PubDate><Year>2018</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>PLoS pathogens</Title>
<ISOAbbreviation>PLoS Pathog</ISOAbbreviation>
</Journal>
<ArticleTitle>Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.</ArticleTitle>
<Pagination><MedlinePgn>e1007264</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1007264</ELocationID>
<Abstract><AbstractText>Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0 (ICP0)-deleted HSV1 (HSV1-dICP0), we found that asTORi markedly augment infection in cancer cells and a mouse mammary cancer xenograft. Mechanistically, asTORi repressed mRNA translation in normal cells, resulting in defective antiviral response but also inhibition of HSV1-dICP0 replication. asTORi also reduced antiviral response in cancer cells, however in contrast to normal cells, transformed cells and cells transduced to elevate the expression of eukaryotic initiation factor 4E (eIF4E) or to silence the repressors eIF4E binding proteins (4E-BPs), selectively maintained HSV1-dICP0 protein synthesis during asTORi treatment, ultimately supporting increased viral replication. Our data show that altered eIF4E/4E-BPs expression can act to promote HSV1-dICP0 infection under prolonged mTOR inhibition. Thus, pharmacoviral combination of asTORi and HSV1 can target cancer cells displaying dysregulated eIF4E/4E-BPs axis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zakaria</LastName>
<ForeName>Chadi</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sean</LastName>
<ForeName>Polen</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hoang</LastName>
<ForeName>Huy-Dung</ForeName>
<Initials>HD</Initials>
<AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Leroux</LastName>
<ForeName>Louis-Phillipe</ForeName>
<Initials>LP</Initials>
<Identifier Source="ORCID">0000-0002-9736-1827</Identifier>
<AffiliationInfo><Affiliation>INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Watson</LastName>
<ForeName>Margaret</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Workenhe</LastName>
<ForeName>Samuel Tekeste</ForeName>
<Initials>ST</Initials>
<AffiliationInfo><Affiliation>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hearnden</LastName>
<ForeName>Jaclyn</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pearl</LastName>
<ForeName>Dana</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Truong</LastName>
<ForeName>Vinh Tai</ForeName>
<Initials>VT</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robichaud</LastName>
<ForeName>Nathaniel</ForeName>
<Initials>N</Initials>
<Identifier Source="ORCID">0000-0002-7653-0767</Identifier>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yanagiya</LastName>
<ForeName>Akiko</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tahmasebi</LastName>
<ForeName>Soroush</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jafarnejad</LastName>
<ForeName>Seyed Mehdi</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jia</LastName>
<ForeName>Jian-Jun</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pelin</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Diallo</LastName>
<ForeName>Jean-Simon</ForeName>
<Initials>JS</Initials>
<Identifier Source="ORCID">0000-0002-4862-2795</Identifier>
<AffiliationInfo><Affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le Boeuf</LastName>
<ForeName>Fabrice</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">0000-0003-3706-2304</Identifier>
<AffiliationInfo><Affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bell</LastName>
<ForeName>John Cameron</ForeName>
<Initials>JC</Initials>
<AffiliationInfo><Affiliation>Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mossman</LastName>
<ForeName>Karen Louise</ForeName>
<Initials>KL</Initials>
<Identifier Source="ORCID">0000-0002-1725-5873</Identifier>
<AffiliationInfo><Affiliation>Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Graber</LastName>
<ForeName>Tyson Ernst</ForeName>
<Initials>TE</Initials>
<Identifier Source="ORCID">0000-0002-5337-3404</Identifier>
<AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jaramillo</LastName>
<ForeName>Maritza</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sonenberg</LastName>
<ForeName>Nahum</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Alain</LastName>
<ForeName>Tommy</ForeName>
<Initials>T</Initials>
<Identifier Source="ORCID">0000-0002-0396-9138</Identifier>
<AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>08</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS Pathog</MedlineTA>
<NlmUniqueID>101238921</NlmUniqueID>
<ISSNLinking>1553-7366</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C087000">EIF4EBP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039561">Eukaryotic Initiation Factor-4E</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017874">Immediate-Early Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber>
<NameOfSubstance UI="C051804">Vmw110 protein, Human herpesvirus 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039561" MajorTopicYN="N">Eukaryotic Initiation Factor-4E</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006561" MajorTopicYN="N">Herpes Simplex</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017874" MajorTopicYN="N">Immediate-Early Proteins</DescriptorName>
<QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030781" MajorTopicYN="N">Organisms, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName>
<QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>10</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>08</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>09</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>1</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30138450</ArticleId>
<ArticleId IdType="doi">10.1371/journal.ppat.1007264</ArticleId>
<ArticleId IdType="pii">PPATHOGENS-D-17-02275</ArticleId>
<ArticleId IdType="pmc">PMC6124814</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Oncotarget. 2017 Jun 27;8(38):63096-63109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28968974</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1576-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20080710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Immunol Res. 2013 Nov;1(5):309-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24777969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2015 Sep;14(9):642-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26323545</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2015 Aug;16(8):838-849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26147685</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Rep. 2017 Feb 7;18(6):1444-1457</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28178522</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2016 May;17(5):514-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27043414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 May;84(10):5260-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20181700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2007 Sep 15;67(18):8818-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17875723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2008 Oct;9(10):1157-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18758466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2017 Apr 6;169(2):361-371</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28388417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods. 2010 Apr;50(4):S1-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20215014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Vis Exp. 2014 May 17;(87):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24893926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2017 Nov 15;31(22):2235-2249</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29269484</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1990 Jun 7;345(6275):544-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2348862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Mol Cell Biol. 2010 Feb;11(2):113-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20094052</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2011 Oct 31;10(11):868-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22037041</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2018 Jul 6;430(14):1965-1992</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29746850</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2007 Sep;27(18):6361-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17636013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2009 Apr 15;15(8):2777-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19351762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2017 Sep 7;170(6):1109-1119.e10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28886381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haematologica. 2017 Apr;102(4):755-764</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28104700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2007 Aug 15;67(16):7551-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17699757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genome Res. 2016 May;26(5):636-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26984228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2018 Apr 9;33(4):599-605</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29634947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2010 Jan 15;70(2):598-608</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20068158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Cancer Res. 2016 Jan 15;6(2):300-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27186404</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2013 Mar;13 Suppl 4:121-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23465005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2017 Jul 15;23(14):3566-3574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28495911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2012 Jun 29;46(6):847-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22578813</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 15;109(20):7723-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22550181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2008 Jan;16(1):52-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17998900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Prog Clin Biol Res. 1988;271:265-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2900511</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2015 Sep 1;33(25):2780-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26014293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncotarget. 2016 Jul 18;8(31):50542-50556</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28881582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Chem. 2009 Apr;55(4):611-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19246619</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Dec 22;9(12):e114854</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25531441</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2014 Jan;22(1):123-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24343053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2001 Nov 1;15(21):2852-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11691836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2012 Dec 15;72(24):6468-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23100465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Oncol. 2017 Jun 06;7:114</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28634571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2010 Dec 1;24(23):2627-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21123650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2005 Dec;12(6):1101-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16140040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cell Dev Biol. 2014 Dec;36:102-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25263010</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2008 Mar 20;452(7185):323-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18272964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2009 May;29(10):2865-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19289497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2010 May 28;328(5982):1172-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20508131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2013 Nov 5;18(5):698-711</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24206664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Cycle. 2008 Jul 15;7(14):2112-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18635959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2015 Apr;14(4):261-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25743081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2016 May 12;35(19):2465-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26257065</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Jan 19;282(3):1757-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17114181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2012 Jul 15;26(14):1527-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22802527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 2011 Sep 15;129(6):1503-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21128236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Death Differ. 2000 Jul;7(7):654-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10889510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Biol. 2009 Feb 10;7(2):e38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19209957</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2016 Jun 20;7:11776</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27319316</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
<li>Québec</li>
</region>
<settlement><li>Hamilton (Ontario)</li>
<li>Montréal</li>
</settlement>
<orgName><li>Université McGill</li>
<li>Université McMaster</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Québec"><name sortKey="Zakaria, Chadi" sort="Zakaria, Chadi" uniqKey="Zakaria C" first="Chadi" last="Zakaria">Chadi Zakaria</name>
</region>
<name sortKey="Alain, Tommy" sort="Alain, Tommy" uniqKey="Alain T" first="Tommy" last="Alain">Tommy Alain</name>
<name sortKey="Bell, John Cameron" sort="Bell, John Cameron" uniqKey="Bell J" first="John Cameron" last="Bell">John Cameron Bell</name>
<name sortKey="Diallo, Jean Simon" sort="Diallo, Jean Simon" uniqKey="Diallo J" first="Jean-Simon" last="Diallo">Jean-Simon Diallo</name>
<name sortKey="Graber, Tyson Ernst" sort="Graber, Tyson Ernst" uniqKey="Graber T" first="Tyson Ernst" last="Graber">Tyson Ernst Graber</name>
<name sortKey="Hearnden, Jaclyn" sort="Hearnden, Jaclyn" uniqKey="Hearnden J" first="Jaclyn" last="Hearnden">Jaclyn Hearnden</name>
<name sortKey="Hoang, Huy Dung" sort="Hoang, Huy Dung" uniqKey="Hoang H" first="Huy-Dung" last="Hoang">Huy-Dung Hoang</name>
<name sortKey="Jafarnejad, Seyed Mehdi" sort="Jafarnejad, Seyed Mehdi" uniqKey="Jafarnejad S" first="Seyed Mehdi" last="Jafarnejad">Seyed Mehdi Jafarnejad</name>
<name sortKey="Jaramillo, Maritza" sort="Jaramillo, Maritza" uniqKey="Jaramillo M" first="Maritza" last="Jaramillo">Maritza Jaramillo</name>
<name sortKey="Jia, Jian Jun" sort="Jia, Jian Jun" uniqKey="Jia J" first="Jian-Jun" last="Jia">Jian-Jun Jia</name>
<name sortKey="Le Boeuf, Fabrice" sort="Le Boeuf, Fabrice" uniqKey="Le Boeuf F" first="Fabrice" last="Le Boeuf">Fabrice Le Boeuf</name>
<name sortKey="Leroux, Louis Phillipe" sort="Leroux, Louis Phillipe" uniqKey="Leroux L" first="Louis-Phillipe" last="Leroux">Louis-Phillipe Leroux</name>
<name sortKey="Mossman, Karen Louise" sort="Mossman, Karen Louise" uniqKey="Mossman K" first="Karen Louise" last="Mossman">Karen Louise Mossman</name>
<name sortKey="Pearl, Dana" sort="Pearl, Dana" uniqKey="Pearl D" first="Dana" last="Pearl">Dana Pearl</name>
<name sortKey="Pelin, Adrian" sort="Pelin, Adrian" uniqKey="Pelin A" first="Adrian" last="Pelin">Adrian Pelin</name>
<name sortKey="Robichaud, Nathaniel" sort="Robichaud, Nathaniel" uniqKey="Robichaud N" first="Nathaniel" last="Robichaud">Nathaniel Robichaud</name>
<name sortKey="Sean, Polen" sort="Sean, Polen" uniqKey="Sean P" first="Polen" last="Sean">Polen Sean</name>
<name sortKey="Sonenberg, Nahum" sort="Sonenberg, Nahum" uniqKey="Sonenberg N" first="Nahum" last="Sonenberg">Nahum Sonenberg</name>
<name sortKey="Tahmasebi, Soroush" sort="Tahmasebi, Soroush" uniqKey="Tahmasebi S" first="Soroush" last="Tahmasebi">Soroush Tahmasebi</name>
<name sortKey="Truong, Vinh Tai" sort="Truong, Vinh Tai" uniqKey="Truong V" first="Vinh Tai" last="Truong">Vinh Tai Truong</name>
<name sortKey="Watson, Margaret" sort="Watson, Margaret" uniqKey="Watson M" first="Margaret" last="Watson">Margaret Watson</name>
<name sortKey="Workenhe, Samuel Tekeste" sort="Workenhe, Samuel Tekeste" uniqKey="Workenhe S" first="Samuel Tekeste" last="Workenhe">Samuel Tekeste Workenhe</name>
<name sortKey="Yanagiya, Akiko" sort="Yanagiya, Akiko" uniqKey="Yanagiya A" first="Akiko" last="Yanagiya">Akiko Yanagiya</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000665 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000665 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30138450
   |texte=   Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30138450" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki